Market Access From roasts to billions: Navigating the biopharma investment... At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.
News Medicxi raises €500m for latest biotech fund Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.
Market Access Biotech ≠ tech: Why venture capital needs a new playbook for... Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1
R&D Why I'm focused on the trillion-dollar AMR crisis everyone's... AMR demands sustained commitment beyond conventional market incentives.
News UK biotech investment "holding firm", says BIA The UK life sciences raised £1.23bn in venture capital investment in the first half of 2025, although there was a fallback in the second quarter.
News Sofinnova raises €1.2bn to back 'up to 60' companies Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.